Inspire Medical Systems, Inc. to Report Third Quarter 2021 Financial Results on November 2, 2021
- S&P 500, Dow close at new highs as Facebook starts heavy earnings week
- Facebook (FB) Stock Jumps With Guidance Not As Bad as Feared
- Tesla (TSLA) Joins Apple, Amazon, Microsoft, Google in Trillion Dollar Club
- PayPal (PYPL) Stock Soars Over 6% on Confirmation It Won't Acquire Pinterest (PINS) 'At This Time'; PINS Stock Down 11%
- Biggest Single EV Purchase Ever: Tesla (TSLA) Stock Soars as Hertz Orders 100,000 EVs in $4.2 Billion Deal, Analyst Bulled-up
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
MINNEAPOLIS, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the third quarter 2021 after the close of trading on Tuesday, November 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
|Tuesday, November 2nd @ 5:00 p.m. Eastern Time:|
About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact:Bob YedidLifeSci Advisorsinspire@lifesciadvisors.com646-597-6989
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Facebook (FB) Tops Q3 EPS by 3c, MAUs were 2.91 billion, Offers Guidance
- United Development Funding IV Recommends Shareholders Reject Hedge Fund NexPoint’s Ninth Extended Hostile Tender Offer; James Dondero alleged to have ‘siphoned’ millions from his former company,
- Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Related EntitiesEarnings, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!